Rhythm BiosciencesASX:RHY +1.08% OCF Yield % is -15.71 as of Jun. 25, 2026. The stock has 6 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Rhythm Biosciences ranks worse than 80.93% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Rhythm Biosciences's OCF Yield % or its related term are showing as below:
ASX:RHY'
s OCF Yield % Range Over the Past 10 Years
Min: -15.71 Med: 0 Max: -15.71
Current: -15.71
During the past 8 years, the highest OCF Yield % of Rhythm Biosciences was -15.71%. The lowest was -15.71%. And the median was %.
ASX:RHY's OCF Yield % is ranked worse than 80.93% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.07
vs ASX:RHY: -15.71
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Rhythm Biosciences OCF Yield % Related Terms
Rhythm Biosciences OCF Yield % Historical Data
* Premium members only.
The historical data trend for Rhythm Biosciences's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Rhythm Biosciences's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Biosciences OCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Rhythm Biosciences's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Biosciences (ASX:RHY) has a OCF Yield % of -15.71 as of Jun. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Rhythm Biosciences and its competitors. According to the industry distribution chart, Rhythm Biosciences ranks #174 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 80.9%.
Is Rhythm Biosciences' OCF Yield % too high?
Rhythm Biosciences' current OCF Yield % is -15.71. Based on the distribution chart, Rhythm Biosciences ranks #174 out of 215 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Rhythm Biosciences' OCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Rhythm Biosciences ranks #174 out of 215 companies for OCF Yield %. This places Rhythm Biosciences in the lower half of its industry. The industry median OCF Yield % is 1.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 1.07, based on 215 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Rhythm Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 1.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Biosciences's current OCF Yield % is -15.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (ASX:RHY) has a current OCF Yield % of -15.71. The current OCF Yield % is -15.71. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Rhythm Biosciences (ASX:RHY), the current OCF Yield % is -15.71 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHY has been successfully added to your 